Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses

Corcept Therapeutics ( (CORT) ) has released its Q2 earnings. Here is a breakdown of the information Corcept Therapeutics presented to its investors.

Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company focused on developing medications that modulate the effects of cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company is known for its product Korlym, used in the treatment of hypercortisolism, and is headquartered in Redwood City, California.

In its latest earnings report for the quarter ending June 30, 2025, Corcept Therapeutics reported a net product revenue of $194.4 million, marking a significant increase from $163.8 million in the same quarter the previous year. Despite this revenue growth, the company experienced a decline in net income, reporting $35.1 million compared to $35.5 million in the previous year, attributed to increased operating expenses.

Key financial highlights include a rise in operating expenses to $167.8 million from $128.2 million, driven by higher selling, general, and administrative costs. The company also reported a decrease in cash and cash equivalents to $102.7 million from $127.7 million at the end of 2024, primarily due to stock repurchase activities. Corcept’s strategic initiatives include the development of relacorilant, a selective cortisol modulator, with a New Drug Application submitted to the FDA for treating hypercortisolism.

Looking ahead, Corcept Therapeutics remains focused on advancing its pipeline of cortisol modulators, with ongoing trials such as the MOMENTUM study aimed at identifying hypercortisolism in patients with resistant hypertension. The management expresses optimism about the potential approval of relacorilant and its ability to address unmet medical needs in hypercortisolism treatment, which could drive future growth.